39965-81-6

Basic information

• Product Name: 2,6-DIMETHYL-4-CYANOPYRIDINE
• Synonyms: 2,6-DIMETHYL-4-CYANOPYRIDINE;4-CYANO-2,6-LUTIDINE;2,6-Dimethylisonicotinonitrile;2,6-Dimethyl-4-pyridinecarbonitrile;4-Cyano-2,6-dimethylpyridine;2,6-dimethylisonicotinonitrile(SALTDATA: FREE);2,6-Dimethylpyridine-4-carbonitrile;2-cyano-2,6-diMethyl-1,2-dihydropyridine-4-carboxylic acid
• CAS NO: 39965-81-6
• Molecular Formula: C₈H₈N₂
• Molecular Weight: 132.16
• Product Categories: Pyridines;Building Blocks;Pyridine
• Mol File: 39965-81-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 80-82℃
• Boiling Point: 229℃
• Flash Point: 92℃
• Appearance: /
• Density: 1.05
• Vapor Pressure: 0.07mmHg at 25°C
• Refractive Index: 1.525
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 3.30±0.10(Predicted)
• CAS DataBase Reference: 2,6-DIMETHYL-4-CYANOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIMETHYL-4-CYANOPYRIDINE(39965-81-6)
• EPA Substance Registry System: 2,6-DIMETHYL-4-CYANOPYRIDINE(39965-81-6)

Safety Data

• Statements: 36
• Safety Statements: 26
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: Ⅲ
• Hazardous Substances Data: 39965-81-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-DIMETHYL-4-CYANOPYRIDINE is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to serve as a building block for the development of new drugs with specific therapeutic properties.
Used in Chemical Synthesis:
In the chemical industry, 2,6-DIMETHYL-4-CYANOPYRIDINE is used as a key intermediate in the synthesis of a wide range of organic compounds. Its reactivity and functional groups make it a valuable component in the creation of various chemical products.
Specific Application:
2,6-DIMETHYL-4-CYANOPYRIDINE is used in the synthetic preparation of 2-ethylthioisonicotinamide, which is an important compound in the development of pharmaceuticals and other chemical products. 2,6-DIMETHYL-4-CYANOPYRIDINE's unique structure and properties make it a crucial component in this specific synthesis process.

InChI:InChI=1/C8H8N2/c1-6-3-8(5-9)4-7(2)10-6/h3-4H,1-2H3

Upstream product

• 1073-23-0 2,6-lutidine N-oxide 
• 151-50-8 potassium cyanide 
• 3512-80-9 4-amino-2,6-lutidine 
• 7732-18-5 water 
• 87117-15-5 1-methoxy-2,6-dimethylpyridinium methyl sulfate 
• 112950-66-0 1,2,6-trimethylpyridinium methosulfate 
• 113708-04-6 2,6-dimethylpyridine-4-carboxamide 
• 557-21-1 zinc(II) cyanide 
• 5093-70-9 4-bromo-2,6-dimethylpyridine 
• 1186513-01-8 2,6-dimethyl-isonicotinic acid isopropyl ester 
• 99055-12-6 2,6-dichloro-isonicotinic acid isopropyl ester 
• 99-11-6 citrazinic acid 
• 325142-95-8 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 

Downstream Products

• 1070791-22-8 t-butyl (2,6-dimethylpyridin-4-yl)methylcarbamate 
• 324571-98-4 1-(2,6-dimethylpyridin-4-yl)methanamine 
• 1070790-98-5 2R,3S-3-(9-isopropyl-6-(2,6-dimethylpyridine-4-ylmethylamino)-9H-purin-2-ylamino)pentan-2-ol 
• 1070791-24-0 N-((2,6-dimethylpyridin-4-yl)methyl)-2-fluoro-9-isopropyl-9H-purin-6-amine 
• 1070791-23-9 N-((2,6-dimethylpyridin-4-yl)methyl)-2-fluoro-9H-purin-6-amine 
• 59576-38-4 (2,6-dimethylpyridin-4-yl)(phenyl)methanone 
• 1520090-07-6 4-(((tert-butyldimethylsilyl)oxy)(phenyl)methyl)-2,6-dimethylpyridine 
• 1122088-92-9 C₁₉H₂₂N₄S 

Relevant articles and documents

Synthesis of 12-Membered Tetra-aza Macrocyclic Pyridinophanes Bearing Electron-Withdrawing Groups

The number of substituted pyridine pyridinophanes found in the literature is limited due to challenges associated with 12-membered macrocycle and modified pyridine synthesis. Most notably, the electrophilic character at the 4-position of pyridine in pyridinophanes presents a unique challenge for introducing electrophilic chemical groups. Likewise, of the few reported, most substituted pyridine pyridinophanes in the literature are limited to electron-donating functionalities. Herein, new synthetic strategies for four new macrocycles bearing the electron-withdrawing groups CN, Cl, NO2, and CF3 are introduced. Potentiometric titrations were used to determine the protonation constants of the new pyridinophanes. Further, the influence of such modifications on the chemical behavior is predicted by comparing the potentiometric results to previously reported systems. X-ray diffraction analysis of the 4-Cl substituted species and its Cu(II) complex are also described to demonstrate the metal binding nature of these ligands. DFT analysis is used to support the experimental findings through energy calculations and ESP maps. These new molecules serve as a foundation to access a range of new pyridinophane small molecules and applications in future work.

CGRP RECEPTOR ANTAGONISTS

The present invention provides a compound of Formula II: (II) or a pharmaceutically acceptable salt thereof.

CGRP RECEPTOR ANTAGONISTS

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.

Improving Robustness: In Situ Generation of a Pd(0) Catalyst for the Cyanation of Aryl Bromides

Conditions have been developed for the palladium-catalyzed cyanation of aryl bromides utilizing the air-stable XantPhos-PdCl2 precatalyst. By employing a trialkylamine as a reducing agent, the active Pd(0) species is generated in situ, alleviating the need to employ the air-sensitive Pd2(dba)3. Twenty-two substituted benzonitriles have been synthesized using this method.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Cyanation of arenes via iridium-catalyzed borylation

We report a method to conduct one-pot meta cyanation of arenes by iridium-catalyzed C-H borylation and copper-mediated cyanation of the resulting arylboronate esters. This process relies on a method to conduct the cyanation of arylboronic esters, and conditions for this new transformation are reported. Conditions for the copper-mediated cyanation of arylboronic acids are also reported. By the resulting sequence of borylation and cyanation, 1,3-disubstituted and 1,2,3-trisubstituted arenes and heteroarenes containing halide, ketone, ester, amide, and protected alcohol functionalities are converted to the corresponding meta-substituted aryl nitriles. The utility of this methodology is demonstrated through the conversion of a protected 2,6-disubstituted phenol to 4-cyano-2,6-dimethylphenol, which is an intermediate in the synthesis of the pharmaceutical etravirine. The utility of the method is further demonstrated by the conversion of 3-chloro-5-methylbenzonitrile, produced through the one-pot C-H borylation and cyanation sequence, to the corresponding 3,5-disubstituted aldehydes, ketones, amides, carboxylic acids, tetrazoles, and benzylamines.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula I.

Photophysics of a series of efficient fluorescent pH probes for dual-emission-wavelength measurements in aqueous solutions

This paper evaluates the 5-aryl-2-pyridyloxazole backbone to engineer donor-acceptor fluorescent pH probes after one- or two-photon absorption. Parent fluorophores, as well as derivatives that can be used to label biomolecules, can be easily obtained in good yields. These molecules exhibit a large one-photon absorption in the near-UV range, and a strong fluorescence emission that covers the whole visible domain. The 5-aryl-2-pyridyloxazole derivatives also possess significant cross sections for two-photon absorption. Upon pyridine protonation, large shifts were observed in the absorption spectra after one- and two-photon excitation, as well as in the emission spectra. This feature was used to measure the pKa of the investigated compounds that range between 2 and 8. In most of the investigated derivatives, the pKa increased upon light excitation and protonation exchanges took place during the lifetime of the excited state, as shown by phase-modulation fluorometry analysis. Several 5-aryl-2-pyridyloxazole derivatives are suggested as efficient probes to reliably measure the pH of aqueous solutions by means of ratiometric methods that are dependent on fluorescence emission.

2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES

The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5--a]pyrimidin-3-yl]methanones with at least one substituent on the 4-pyridinyl ring having the chemical structure of formula (I): The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula: (I) in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA receptors.